Anti-BLM Antibody, clone 1F7-L1 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.
RecQ-like DNA helicase BLM (UniProt: P54132; also known as EC:5.6.2.4, Bloom syndrome protein, DNA 3′-5′ helicase BLM, DNA helicase, RecQ-like type 2 (RecQ2), RecQ protein-like 3) is encoded by the BLM (also known as RECQ2, RECQL3) gene (Gene ID: 641) in human. The BLM protein is a highly conserved member of the RecQ helicase family, characterized by its 3′ to 5′ ATP-dependent DNA unwinding activity. This helicase plays a vital role in maintaining genomic stability by participating in DNA replication, repair, and homologous recombination (HR). BLM is integral to several DNA repair pathways, including the resolution of double-strand breaks (DSBs) via HR, synthesis-dependent strand annealing (SDSA), and the dissolution of double Holliday junctions. Structurally, it contains conserved helicase domains, a RecQ C-terminal (RQC) domain for protein-protein interactions, and a helicase-RNase D C-terminal (HRDC) domain that facilitates DNA binding. BLM predominantly localizes to the nucleus, where it colocalizes with DNA repair markers such as γH2AX, RAD51, and 53BP1 during the S and G2 phases of the cell cycle. Additionally, it interacts with topoisomerase 3α (TOP3A) and RecQ-mediated genome instability proteins (RMI1 and RMI2) to form a complex vital for resolving recombination intermediates. Post-translational modifications, including phosphorylation and ubiquitination, regulate its activity and localization. Mutations in the BLM gene result in Bloom syndrome, a rare autosomal recessive disorder characterized by chromosomal instability, growth retardation, immunodeficiency, and a predisposition to multiple cancers. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal half of human BLM.

Quality Control Testing
Evaluated by Western Blotting in rat brain tissue lysate. 

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected BLM in rat brain tissue lysate.
Tested Applications
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected BLM in nuclear extract from HEK-293 cells and a 1:1,000 dilution from HeLa and NIH/3T3 cell lysates.
Flow Cytometry Analysis: 1 µg from a representative lot detected BLM in one million HeLa cells.
Affinity Binding Assay: A representative lot of this antibody bound with BLM peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1F7-L1 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects BLM. It targets an epitope within 25 amino acids from the C-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.